Mangoceuticals (MGRX) Total Non-Current Liabilities (2022 - 2026)

Mangoceuticals (MGRX) has 4 years of Total Non-Current Liabilities data on file, last reported at $236965.0 in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $236965.0; the trailing twelve-month figure through Mar 2026 stood at $236965.0 (changed N/A YoY), and the FY2023 full-year result was $64961.0, down 49.52% from the prior year.
• Total Non-Current Liabilities improved to $236965.0 in Q1 2026, from $12167.0 in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $236965.0 in Q1 2026 to a low of $12167.0 in Q3 2024.
• A 4-year average of $90307.7 and a median of $81508.0 in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slumped 49.52% in 2023 and plunged 85.07% in 2024, its largest moves.
• Tracing MGRX's Total Non-Current Liabilities over 4 years: stood at $128680.0 in 2022, then tumbled by 49.52% to $64961.0 in 2023, then sank by 81.27% to $12167.0 in 2024, then jumped by 1847.6% to $236965.0 in 2026.
• Business Quant data shows MGRX's Total Non-Current Liabilities at $236965.0 in Q1 2026, $12167.0 in Q3 2024, and $30117.0 in Q2 2024.